ReviewFrontiers in pharmacology2026
Placental and fetal consequences of maternal selective serotonin reuptake inhibitor use: current evidence and unresolved questions.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serotonin is a neurotransmitter critical for mood regulation, neurodevelopment, and diverse organ functions. It is synthesized from tryptophan through tightly regulated enzymatic pathways that maintain homeostasis, particularly during pregnancy. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed across age groups to manage depression, anxiety, and other mental health conditions, with treatment tailored to individual needs. During pregnancy, SSRIs are widely prescribed or maintained to manage maternal health. Despite decades of research on SSRIs and pregnancy, there continues to be conflicting conclusions with some studies reporting beneficial effects on maternal and fetal health and outcomes, while others suggest potential risks. This review aimed to identify overall trends and evolution of our understanding of SSRI use and pregnancies from studies published from 1983-2025, including comparisons between placental roles of two major model organisms: mice and humans, serotonin biology, pharmacological properties, and prescription mechanisms of SSRIs, and the impact of SSRI use during pregnancy and the continued gaps in current research. Despite extensive research, there is a significant gap in understanding the safety and effects of SSRI use specifically in advanced maternal age pregnancies, as the age of first-time mothers continues to shift past 30 years old, highlighting a critical area for future research and clinical guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.